US FDA reinspection outcome uncertain
The warning letter period ends in two weeks; reinspection timing and outcome are unknown, posing a risk to pharma recovery.
HIKAL / Q3-FY26 / risks
Keep the risk register visible.
Hikal · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Persistent crop pricing pressure from China
Chinese overcapacity continues to pressure crop protection pricing and margins, with no near-term relief expected.
Revenue reversal adjustment may raise questions
An ₹80 crore revenue reversal from Q2 was adjusted in Q3; ongoing system review could imply further adjustments, though management denies this.
Animal health volume ramp-up slower than expected
Animal health commercial volumes are still ramping; full utilization may not be reached until FY28, delaying revenue contribution.